Clinical trial NCT03281538: Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Official title: An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Uremic Pruritus
Keywords: CR845
difelikefalin
Pruritus
Chronic Itch
Itch
Itching
hemodialysis
Uremic Pruritus
Dialysis
CKD
CKD-associated pruritus
CKD-aP
ESRD (end stage renal disease)
Chronic Kidney Disease
Kidney failure, chronic
Kidney dysfunction
Generalized pruritus
Lead sponsor: Cara Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2017-09-13
Enrollment: 288
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.

Detailed description: This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks. This study will consist of a Screening Visit, a 52 week Treatment Period, and a Follow-up Visit. Informed consent will be obtained prior to performing any study-specific procedures. All patients will have a Screening Visit, which can be performed anytime within 14 days prior to the first dose of study drug, to confirm eligibility.

Clinical laboratory tests, electrocardiograms (ECGs), vital signs, adverse events, and concomitant medications will be monitored throughout the study. Blood samples for inflammatory biomarkers will be collected from all patients prior to dialysis on Day 1 and periodically until the End of Treatment or Early Termination Visit. Blood samples will also be collected periodically for clinical laboratory tests.

Eligibility criteria: Inclusion Criteria:

To be eligible for inclusion into the study, a patient must meet the following criteria:

1. Willing and able to provide written informed consent prior to participating in this study;
2. Able to communicate clearly with the Investigator and staff, able to understand the study procedures, and able and willing to comply with the study schedules and all study requirements;
3. Males or females 18 years of age or older;
4. Currently on hemodialysis for end-stage renal disease and has been categorized as experiencing moderate to severe uremic pruritus;
5. If female:

   1. Is not of childbearing potential (surgically sterile or postmenopausal, as defined in Section 6.5.1.6); or
   2. Has a negative serum pregnancy test at screening and agrees to use acceptable contraceptive measures (as defined in Section 6.5.1.6) from the time of informed consent until the safety Follow-up Visit or 7 days after the last dose of study drug, whichever is later.
6. If male, agrees not to donate sperm after the first dose of study drug until 7 days after the last dose, and agrees to use a condom with spermicide or abstain from heterosexual intercourse during the study until 7 days after study drug administration. (Note: No restrictions are required for a vasectomized male provided his vasectomy was performed ≥4 months prior to dosing);
7. Has a dry body weight of ≥40.0 kg at screening (prescription target dry body weight);
8. Has adequacy of dialysis, defined as meeting 1 of the following criteria during the 3 months prior to screening:

   1. ≥2 single pool Kt/V measurements ≥1.2; or
   2. ≥2 urea reduction ratio measurements ≥65%; or
   3. 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65%

Exclusion Criteria:

A patient will be excluded from the study if any of the following criteria are met:

1. Received an investigational drugwithin 30 days prior to the first dose of study drug, or is planning to participate in another interventional clinical study while enrolled in this study.
2. Has a concomitant disease or any medical condition that, in the opinion of the Investigator, could pose undue risk to the patient, impede completion of the study procedures, or would compromise the validity of the study measurements, including, but not limited to:

   1. Known or suspected history of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, -diagnosed alcohol, narcotic or other drug abuse, or substance dependence within 12 months prior to screening;
   2. New York Heart Association Class IV congestive heart failure (Appendix 1, Section 14.0);
   3. Severe mental illness or cognitive impairment (eg, dementia);
   4. Any other relevant acute or chronic medical or neuropsychiatric condition;

Primary outcomes:
measure: Number of Participants With AEs
timeFrame: Up to 52 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chula Vista
country: United States
facility: Cara Therapeutics Study Site
state: California
city: El Centro
country: United States
facility: Cara Therapeutics Study Site
state: California
city: Long Beach
country: United States
facility: Cara Therapeutics Study Site
state: California
city: Northridge
country: United States
facility: Cara Therapeutics Study Site
state: California
city: Denver
country: United States
facility: Cara Therapeutics Study Site
state: Colorado
city: Hollywood
country: United States
facility: Cara Therapeutics Study Site
state: Florida
city: Tampa
country: United States
facility: Cara Therapeutics Study Site
state: Florida
city: Winter Park
country: United States
facility: Cara Therapeutics Study Site
state: Florida
city: Albany
country: United States
facility: Cara Therapeutics Study Site
state: Georgia
city: Augusta
country: United States
facility: Cara Therapeutics Study Site
state: Georgia
city: Meridian
country: United States
facility: Cara Therapeutics Study Site
state: Idaho
city: Springfield
country: United States
facility: Cara Therapeutics Study Site
state: Massachusetts
city: Roseville
country: United States
facility: Cara Therapeutics Study Site
state: Michigan
city: Kansas City
country: United States
facility: Cara Therapeutics Study Site
state: Missouri
city: Albuquerque
country: United States
facility: Cara Therapeutics Study Site
state: New Mexico
city: Gallup
country: United States
facility: Cara Therapeutics Study Site
state: New Mexico
city: Mineola
country: United States
facility: Cara Therapeutics Study Site
state: New York
city: Ridgewood
country: United States
facility: Cara Therapeutics Study Site
state: New York
city: Bethlehem
country: United States
facility: Cara Therapeutics Study Site
state: Pennsylvania
city: Knoxville
country: United States
facility: Cara Therapeutics Study Site
state: Tennessee
city: El Paso
country: United States
facility: Cara Therapeutics Study Site
state: Texas
city: San Antonio
country: United States
facility: Cara Therapeutics Study Site
state: Texas
city: San Antonio
country: United States
facility: Cara Therapeutics Study Site
state: Texas
city: San Antonio
country: United States
facility: Cara Therapeutics Study Site
state: Texas
city: Saint George
country: United States
facility: Cara Therapeutics Study Site
state: Utah
city: Wauwatosa
country: United States
facility: Cara Therapeutics Study Site
state: Wisconsin
city: San Juan
country: Puerto Rico
facility: Cara Therapeutics Study Site
Study officials:
affiliation: Cara Therapeutics
name: Frederique Menzaghi
role: STUDY_DIRECTOR
References:
citation: Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K, Menzaghi F, Goncalves J. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. Kidney Med. 2022 Jun 28;4(8):100513. doi: 10.1016/j.xkme.2022.100513. eCollection 2022 Aug.